Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Pediatrics Faculty Publications

Pediatrics

5-1-2013

Characteristics of children with the best and
poorest first- and second-year growth during rhGH
therapy: data from 25 years of the Genentech
national cooperative growth study (NCGS)
Paul B. Kaplowitz
George Washington University

Dorothy I. Shulman
University of South Florida

James W. Frane
Biostatistics, Santa Monica, CA

Joan Jacobs
Biostatistics, San Francisco, CA

Barbara Lippe
Genentech, Inc., San Francisco, CA

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs
Part of the Pediatrics Commons
Recommended Citation
Kaplowitz, P.B., Shulman, S.I., Frane, J.W., Jacobs, J., Lippe, B. (2013). Characteristics of children with the best and poorest first- and
second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS).
International Journal of Pediatric Endocrinology, 9.

This Journal Article is brought to you for free and open access by the Pediatrics at Health Sciences Research Commons. It has been accepted for
inclusion in Pediatrics Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.

Kaplowitz et al. International Journal of Pediatric Endocrinology 2013, 2013:9
http://www.ijpeonline.com/content/2013/1/9

RESEARCH

Open Access

Characteristics of children with the best and
poorest first- and second-year growth during
rhGH therapy: data from 25 years of the
Genentech national cooperative growth study
(NCGS)
Paul B Kaplowitz1*, Dorothy I Shulman2, James W Frane3, Joan Jacobs4 and Barbara Lippe5

Abstract
Background: Models assessing characteristics contributing to response to recombinant human growth hormone
(rhGH) response rarely address growth extremes in both years 1 and 2 or examine how children track from year to
year. Using National Cooperative Growth Study (NCGS) data, we determined characteristics contributing to
responsiveness to rhGH and the pattern of change from years 1 to 2.
Patients and methods: Height velocity standard deviation score (HV SDS) for 2 years for prepubertal children with
idiopathic GH deficiency (IGHD) (n = 1899) and idiopathic short stature (ISS) (n = 1186) treated with similar doses for
two years were computed. Group 1 = HV SDS < −1; 2 = HV SDS −1 to +1; 3 = HV SDS > +1.
Results: For IGHD, mean age was 7.5 years and similar in all groups. Year 1 HV SDS was associated with greater
body mass index (BMI) SDS, lower pre-treatment HV, baseline height SDS, greater target height SDS minus height
SDS, and lower maximum stimulated GH (P <0.0001). Year 2, 172/271 (73%) in group 1 moved to either group 2
(n = 156) or 3 (n = 16). Year 2 HV SDS was associated with greater year 1 HV SDS (r = 0.045, P <0.0001), greater BMI
SDS, taller parents and lower peak GH.
For ISS, year 1 HV SDS was associated with greater BMI SDS and lower pre-treatment HV (P ≤0.0001). 109/169 (64%)
in group 1 moved to group 2 (n = 90) or group 3 (n = 19). Greater year 2 HV SDS was related to year 1 HV SDS
(r = 0.27, P <0.0001).
Conclusion: For IGHD, multiple characteristics contributed to best first-year response but for ISS, best first-year HV
SDS was associated only with BMI SDS and inversely with pre-treatment HV. For both GHD and ISS, year 1 HV SDS
was not a strong enough predictor of year 2 HV SDS to use first-year HV alone to determine GH continuation.
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Introduction
While several publications have described the factors
that predict responsiveness to recombinant human growth
hormone (rhGH) during therapy [1-4], the factors
predicting which individual patients are likely to be either
the best or worst responders during both the first and the
second years of therapy have been studied in less detail. In
addition, the persistence of growth patterns from year 1 to
2 and the factors that influence persistence or shift have
also not been clarified. We used data from the Genentech
National Cooperative Growth Study (NCGS), collected
over a 25-year period, to examine the responsiveness to
rhGH of boys and girls who were diagnosed with either
idiopathic GH deficiency (IGHD) or idiopathic short stature (ISS). Our goals were to identify factors that predicted
excellent or poor growth in both the first and second years
of therapy, and to determine to what extent the individual
child with either poor or excellent growth in the first year
had a similar growth response during the second year of
rhGH therapy.
Methods
The voluntary NCGS registry was initiated in December
1985 to collect data on children treated with rhGH for
evaluation of safety and efficacy. Data entered by clinical
investigators in the United States and Canada included
height, weight, etiology of short stature, parental height,
peak serum GH response to stimulation testing, Tanner
pubertal stages, and rhGH dose for consenting patients
treated with Genentech’s rhGH products. Informed consent
was obtained according to the procedures in place at
each participating center’s institutional review board.
At the time of its closure in June 2010, the database
reflected ~ 220,000 GH treatment years in 65,205 children. This database was searched for children with IGHD
(peak GH on stimulation testing of <10 ng/mL) or ISS
(no identified cause of short stature and peak GH in any
test of ≥10 ng/mL) (n = 31,815). Of these, we restricted
analysis to those who met the following criteria:
1) Boys ≥4 and <11 years and girls ≥4 and <10 years who
were naive to rhGH therapy at enrollment into NCGS.
2) Patients still prepubertal at the end of the second
year of therapy defined as testicular volume ≤3 mL
in boys and Tanner 1 breast development in girls, in
order to eliminate the majority of those who may
have started their pubertal growth spurts.
3) Patients with height velocities (HVs) available for
calculation of both the first and second years of therapy.
4) Diagnosis of either IGHD (n = 1899) or ISS (n = 1186).
5) Treatment with rhGH administered 6–7 days/week.
Subjects’ HV standard deviation scores (SDS), adjusted
for age, sex, and etiology of short stature, were compared
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not with normal children as a function of age and gender,
but with the data of Bakker et al. [5,6] based on HVs
during their first and second years of therapy. The Bakker
first-year graphs for defining responses to rhGH were derived from NCGS data from 842 females and 2323 males
with IGHD and 465 females and 1392 males with ISS [5].
Second-year data were derived from 316 females and 999
males with IGHD and 143 females and 535 males with ISS
from the same NCGS database [6] (Additional file 1).
Subjects in this study who met the criteria outlined
above were then classified by their HV SDS during the
first and second years as < −1 (poor responders), −1 to +1
(average responders), or > +1 (best responders).
Mid-parental target height was computed according to
Tanner [7] and converted to a SD score. The following
characteristics were examined to learn which were
predictive of responsiveness to GH: age at baseline,
height SDS at baseline, gender, pre-treatment (pre-Rx)
HV reported by investigator, body mass index (BMI)
SDS at baseline, mother’s height SDS, father’s height SDS,
and maximum stimulated GH. Results are presented in
tables as means. Wherever the sample size in a single cell
is ≤10, data are omitted. P values for relationships between
prognostic variables and HV SDS were assessed using
Pearson correlations.

Results
Because our subjects span a range of ages from 4 years
to 10–11 years, and because the Bakker curves are based
on HV SDS, it was felt that presenting the growth data
in terms of HV SDS made more sense than trying to
express it in cm/year. However, to provide some sense of
what our results means in terms of actual growth rates,
it should be noted that the first-year HVs reported by
Bakker for 8-year-old males with IGHD at the onset of
therapy (the approximate average age of the subjects in
this report) were HV >11.4 cm/yr for HV SDS >1,
whereas those with HV SDS < −1 had HV <5.9 cm/yr. For
males with ISS, the HVs for HV SDS >1 were >10.0 cm/yr,
whereas those with HV SDS < −1 had HV <5.4 cm/yr. For
the second year of treatment, the HVs for HV SDS >1
and −1 for boys aged 9 years (i.e. the ones who were
aged 8 years at the beginning of the first year) were 9.6
and 5.7 cm/yr for IGHD and 8.9 and 5.6 cm/yr for ISS.
Analysis of shift tables

The number of patients in each HV SDS group and their
shifts from year 1 to year 2 are shown in Table 1 and
illustrated in Figure 1. Variables assessed are shown in
Tables 2, 3, 4 and 5. Each of these shift tables shows the
mean results for the variable in question according to
each growth response SDS group for the first year in the
last column. For example in Table 3, the IGHD best
first-year growers (HV SDS > +1) had a mean baseline

Kaplowitz et al. International Journal of Pediatric Endocrinology 2013, 2013:9
http://www.ijpeonline.com/content/2013/1/9

Page 3 of 8

Table 1 Numbers of patients in HV SDS groups
IGHD (n = 1899)

ISS (n = 1186)

Second-year HV SDS
< −1

First-Year HV SDS

−1 to +1

Second-year HV SDS

> +1

Total

First-Year HV SDS

< −1

−1 to +1

> +1

Total

< −1

99

156

16

271

< −1

60

90

19

169

−1 to +1

172

1102

106

1380

−1 to +1

127

625

98

850

> +1

10

133

105

248

> +1

10

112

45

167

Total

281

1391

227

1899

Total

197

827

162

1186

HV, height velocity; IGHD, idiopathic growth hormone deficiency; ISS, idiopathic short stature; SDS, standard deviation score.

height SDS of −3.2, which is the value in the “Total”
column for the “HV SDS > + 1” row. These shift tables
also show the total number of patients in each HV SDS
group for the second year in the last row. To follow a
group from their first-year SDS category to their
second-year SDS category, begin by looking down the
left column of the table to find the growth response
category for the first year, and then across the row for
the growth response category for the second year. For
example, in Table 3 for IGHD, the mean baseline height
SDS for patients who were in the SDS > +1 category for the
first year and then were in the SDS category between −1
and +1 for the second year is −3.1.
Patients with IGHD
Characteristics

There were 1507 boys and 392 girls (21%) included in
the analyses. Mean age at start of therapy (7.3 ± 1.9 years)
was similar in all three HV groups and is not shown.

133
54%

140
120
100
80
60
40
20
0

105
42%

10
4%

< –1

–1 to +1

a

> +1

> +1
248
13%
< –1
271
14%

–1 to +1
850
72%

800
400
200

172
13%

106
8%

0

< –1

100
80

45
27%

60
40
20

10
6%

0

< -1

-1 to +1

> +1

-1 to +1 > +1

180
160
140
120
100
80
60
40
20
0

< –1
169
14%

b

156
58%

d

99
37%
16
6%
< –1

–1 to +1

> +1

2nd Year HV SDS for
–1 to +1 SDS in 1st Year
625
74%

700
600
500
400
300
200

127
15%

98
12%

100

Number of Patients

Number of Patients

1102
80%

1000
600

112
67%

120

2nd Year HV SDS for
< -1 SDS in 1st Year

Number of Patients

2nd Year HV SDS for
–1 to +1 SDS in 1st Year

Number of Patients

b

1200

1st Year HV SDS ISS
Patients, n-1186

2nd Year HV SDS for
> +1 SDS in 1st Year

> +1
167
14%

–1 to +1
1380
73%

d

c

B. ISS
Number of Patients

Number of Patients

1st Year HV SDS
IGHD, n-1899

a

2nd Year HV SDS for
> +1 SDS in 1st Year

c

A. IGHD

Also not shown in the tables was the mean GH dose
(0.3 ± 0.05 mg/kg/week), which was nearly identical
in all three groups. The greatest year 1 HV SDS was
associated with lower mean pre-Rx HV (3.8 cm/yr
vs. 4.7 and 4.6 cm/yr for the poor and average responders,
respectively, P <0.0001; Table 2). However, the correlation
of the pre-treatment HV with the first-year Bakker HV
SDS was not large (r = 0.16). The best responders also had
a lower mean baseline height SDS (−3.2 vs. − 2.7 and −2.7
for the poor and average responders, P <0.0001; Table 3),
greater mean BMI SDS (+0.1 vs. −0.5 and −0.4, P < 0.0001,
Table 4), and lower median maximum stimulated GH
(3.8 vs. 6.7 and 6.4 ng/mL, P <0.0001, Table 5). In every
case, the difference between the best and average responder
groups was much greater than between the average and
poor responders. The effect of parental height is shown in
Table 6. The height SDS deficit at baseline is equal to the
mid-parental target height SDS minus the height SDS of
the patient at baseline. For the first year of treatment, the

2nd Year HV SDS for
< –1 SDS in 1st Year
90
53%

100
80
60

60
36%
19
11%

40
20
0

< -1

-1 to +1

> +1

0

< –1

–1 to +1

> +1

Figure 1 Distribution of responses based on height velocity standard deviation score (HV SDS) of patients with idiopathic growth
hormone deficiency (IGHD) and idiopathic short stature (ISS) in the second year of therapy based on their category of response during
the first year. HV SDS responses to recombinant human growth hormone of patients with IGHD (A) and ISS (B) in the first year of therapy and
subsequent second-year response. The pie segments (a) represent the distribution of patients into the 3 first-year growth velocity groups; < −1 SDS, -1
to +1 SDS, >1 SDS. The three charts, b, c, and d, show the SDS shift in the second year of each of the 3 first-year growth velocity groups.
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Table 2 Mean pre-treatment HV (cm/yr) by first- and second-year HV SDS groups
IGHD (n = 1044)

ISS (n = 680)

Second-year HV SDS

Second-year HV SDS

< −1

−1 to +1

< −1

4.8

4.7

4.7

−1 to +1

4.4

4.7

4.2

4.6

3.7

4.0

3.8

> +1

4.5

4.1

4.5

Total

First-Year HV SDS

> +1
Total

4.5

> +1

Total

< −1

−1 to +1

< −1

4.3

5.4

−1 to +1

4.4

4.6

4.8

4.6

3.7

4.5

3.9

4.6

4.6

4.6

First-Year HV SDS

4.4

> +1

Total
4.9

HV, height velocity; IGHD, idiopathic growth hormone deficiency; ISS, idiopathic short stature; SDS, standard deviation score.

deficit was 3.1 in the IGHD best responders and 2.2 in the
poor responders. For the second year, the deficit was 2.8 in
the best responders and 2.3 in the poor responders. The
bigger the difference between the mid-parental target
height SDS and the patient’s baseline height SDS, the
greater the HV was likely to be in both the first and second
year of GH treatment (P <0.0001 and P <0.0001).
To address the possibility that our results might have
been biased by preferential drop-out in the second year
of patients who had a poor response to GH treatment in
the first year, we looked at a separate subset of patients
for whom we had HV data for the first year but no second
year data (N = 352) either because of early drop-out or
because there were no visits within the time frame needed
for the second-year time point. We found a regression
coefficient of −0.290 for the Bakker HV SDS (P <0.0001),
suggesting that those IGHD subjects with poorer growth
during the first year of growth hormone therapy were more
likely to drop out than those with better first-year growth.
As shown in Table 7, we defined subgroups of patients
with IGHD who had all of the characteristics we identified
as predictive of excellent response (n = 28) vs. patients who
would have been predicted to respond poorly (n = 29). The
patients predicted to be “super-responders” did indeed have
a very strong first-year response to GH (increase in HV
from 1.9 to 13.1 cm/yr [compared with an average first-year
HV of 11.4 cm/yr for the best responder group based on
the Bakker curves for 8-year-old males]). The group with
poor predictors still responded to GH, albeit with a lesser
response (increase from 6.2 to 8.6 cm/yr). The poor
response group based on the Bakker curves had an average
first-year HV of 6.7 cm/yr, so we were much less successful

in using our predictors to define a group of very poor responders than to define a group of super-responders. When
we looked at growth of the same group of subjects during
their second year of GH therapy, the difference in HV and
HV SDS between the predicted best and worst responders
was much smaller, confirming that first-year growth may
not be very predictive of growth in subsequent years.
Shifts

During year 2, 172 of 271 (73%) poor responders moved
to either the average (n = 156) or best responder groups
(n = 16), with 99 remaining poor responders. Four percent of the best responders moved to the poor responder
group (Table 1 and Figure 1, panel A). Year 2 HV SDS
was associated with having a greater difference between
baseline height SDS and mid-parental target height SDS,
greater BMI SDS, and lower maximum stimulated GH.
Twenty percent of the variance of HV SDS in year 2 was
predicted by HV SDS in year 1 (r = 0.45, P <0.0001), using
HV SDS as a continuous variable.
Patients with ISS
Characteristics

There were 928 boys and 258 girls (22%) included in the
analyses. Numbers of patients in each HV SDS category
and their shift from year 1 to year 2 are shown in Table 1
and Figure 1, panel B. Variables assessed are shown
in Tables 2, 3, 4 and 5. Mean age at start of therapy
(7.7 ± 1.9 years) was similar in the 3 groups and similar to
the IGHD group. Not shown in the tables but also
assessed was GH dose (0.31 ± 0.06 mg/kg/wk), which was
nearly identical in all groups and almost the same as for

Table 3 Mean baseline height SDS by HV SDS groups
IGHD (n = 1899)

ISS (n = 1186)

Second-year HV SDS

Second-year HV SDS

First-Year HV SDS

< −1

−1 to +1

> +1

Total

First-Year HV SDS

< −1

−1 to +1

> +1

Total

< −1

−2.9

−2.6

−2.4

−2.7

< −1

−3.1

−2.7

−2.4

−2.8

−1 to +1

−2.8

−2.7

−2.7

−2.7

−1 to +1

−2.8

−2.8

−2.6

−2.8

> +1

−2.8

−3.1

−3.4

−3.2

> +1

−3.3

−2.7

−2.6

−2.7

Total

−2.8

−2.7

−3.0

−2.8

Total

−2.9

−2.8

−2.6

−2.8

HV, height velocity; IGHD, idiopathic growth hormone deficiency; ISS, idiopathic short stature; SDS, standard deviation score.
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Table 4 Mean baseline BMI SDS by HV SDS groups
IGHD (n = 1891)

ISS (n = 1181)

Second-year HV SDS

Second-year HV SDS

First-Year HV SDS

< −1

−1 to +1

> +1

Total

First-Year HV SDS

< −1

−1 to +1

> +1

Total

< −1

−0.5

−0.5

−0.5

−0.5

< −1

−0.8

−0.8

−0.6

−0.8

−1 to +1

−0.5

−0.4

−0.1

−0.4

−1 to +1

−0.6

−0.5

−0.6

−0.5

0.0

0.1

0.1

> +1

0.7

−0.3

−0.3

−0.2

−0.5

−0.4

0.0

−0.3

Total

−0.6

−0.5

−0.6

−0.5

> +1
Total

BMI, body mass index; HV, height velocity; IGHD, idiopathic growth hormone deficiency; ISS, idiopathic short stature; SDS, standard deviation score.

IGHD. Greater year 1 HV SDS was associated with lower
pre-Rx HV (3.9 cm/yr vs. 4.9 and 4.6 cm/yr for the average
and poor responders, P <0.0001, Table 2). However, the
correlation of pre-treatment HV with the first-year Bakker
HV SDS was not large (r = 0.15). Greater year 1 HV SDS
was not associated with baseline height SDS (Table 3) in
contrast to the IGHD group. Greater year 1 HV SDS was
associated with greater mean BMI SDS (−0.2 vs. −0.8 and
−0.5, P <0.0001, Table 4); unlike in the IGHD group, it
was not associated with stimulated GH, which by definition was >10 ng/mL in all patients (Table 5). There were
no significant differences in responses between boys and
girls. The greater the difference between the mid-parental
target height SDS and the patient’s baseline height SDS,
the greater the HV was likely to be during the first year of
GH treatment (P <0.022) but not during the second
year (P = 0.090) (Table 6). Only 7% of the variance of
HV SDS in year 2 was predicted by HV SDS in year 1
(r = 0.27, P <0.0001). The difference in mean HV SDS
between ISS patients with both first- and second-year
HV and patients with first- but not second-year HV
was not significant (P = 0.21).
Shifts

During year 2, 109 of 169 (64%) poor responders moved
to the average responder (n = 90) or best responder
groups (n = 19), with only 60 (36%) remaining poor
responders (Table 1 and Figure 1, panel B). Six percent
of the best responders moved to the poor responder
group. Having the best HV SDS in year 2 was not notably
related to any of the baseline characteristics examined
in Tables 2, 3, 4 and 5. Only 7% of the variance of HV

SDS in year 2 was predicted by HV SDS in year 1 (r = 0.27,
P <0.0001), using HV SDS as a continuous variable.

Discussion
Previous studies looking at patients with various etiologies of short stature either at single institutions or from
large databases such as the Kabi International Growth
Study (KIGS) or the ANSWER Program have attempted
to define pre-Rx factors that best predict short-term GH
responsiveness [1-4]. Goals of these studies have been to
inform the selection of patients most likely to benefit
from GH therapy, to predict the magnitude of the
increase in HV during therapy, and to help pick the
optimal dose of GH to produce the desired increase in
HV. Younger age has been found to predict better
responsiveness to GH, as well as lower peak GH levels
in response to provocative testing, taller parents, and a
higher BMI SD score. In patients with IGHD, these predictors make clinically relevant “sense” since they define
the characteristics of this group, and previous studies
have shown that the most severely GH-deficient children
tend to be the most responsive to GH [1,3,4].
An earlier report using the NCGS database showed
that the increase in height SDS during the first year of
GH therapy was significantly greater in patients with
peak GH < 3 ng/mL (+1.14) than in those with peak GH
of 3 to 7 ng/mL (+0.81) and 7 to 10 ng/mL (+0.72) [8].
In addition, children with severe GH deficiency tend to
have increased body fat stores, as noted in a study that
found a high correlation between baseline leptin and
first-year change in height SDS (r = 0.49; P <0.0001) in a
sample of 150 Swedish children with a range of peak

Table 5 Median maximum stimulated GH (ng/mL) by HV SDS groups
IGHD (n = 1899)

ISS (n = 932)

Second-year HV SDS

Second-year HV SDS

< −1

−1 to +1

> +1

< −1

6.6

6.7

6.1

6.7

< −1

17.0

14.7

13.8

15.0

−1 to +1

6.3

6.5

4.9

6.4

−1 to +1

14.9

14.2

14.0

14.3

> +1

5.6

4.1

2.0

3.0

> +1

13.9

13.8

14.0

Total

6.4

6.4

3.7

6.1

Total

14.1

13.9

14.3

First-Year HV SDS

Total

First-Year HV SDS

< −1

15.9

HV, height velocity; IGHD, idiopathic growth hormone deficiency; ISS, idiopathic short stature; SDS, standard deviation score.

−1 to +1

> +1

Total
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Table 6 Mean mid-parental target height SDS minus baseline height SDS by HV SDS groups
IGHD (n = 1664)

ISS (n = 1001)

Second-year HV SDS

Second-year HV SDS

< −1

−1 to +1

> +1

Total

< −1

2.4

2.0

2.0

2.2

−1 to +1

2.3

2.2

2.4

2.2

2.9

3.3

3.1

> +1

2.3

2.8

2.3

Total

First-Year HV SDS

> +1
Total

2.3

< −1

−1 to +1

> +1

Total

< −1

2.5

2.1

1.8

2.2

−1 to +1

2.2

2.2

2.2

2.2

2.5

2.4

2.5

2.2

2.2

2.2

First-Year HV SDS

2.3

HV, height velocity; IGHD, idiopathic growth hormone deficiency; ISS, idiopathic short stature; SDS, standard deviation score.

GH values [9]. Thus it is not surprising that the best
responders in our IGHD group have a significantly higher
BMI SDS than the average responders, although the
difference in mean BMI SDS between the average and
poor responders was relatively small. In the ISS group,
BMI was also positively associated with response. Parental
height clearly also contributes to responsiveness, as short
children of average or tall parents have greater genetic
potential and usually have a greater height deficit to
recoup during the first 2 years of therapy. For IGHD
patients, the bigger the difference between the midparental target height SDS and the patient’s baseline
height SDS, the greater the HV was likely to be during
both the first and second years of GH treatment, but
for ISS patients, the effect of this difference on HV was
much smaller during the first year and non-significant
for the second year.

While our data confirm some of the predictors already
known, our approach to defining GH responsiveness in
patients with IGHD and ISS differs from other approaches
in several respects. We were able to define the best and
the poorest responders not based on arbitrary criteria,
such as a certain increase in HV or in height SDS, factors
that depend to some extent on the age of the patients, but
based on age, sex, and diagnosis-specific HV curves for
both the first and second years of GH therapy from large
numbers of similarly treated patients. These curves,
developed by Bakker et al. [5,6] were derived from a
large sample of GH-treated patients with IGHD and
ISS contained within the same NCGS database as was
used for our analyses. We also wanted to examine both
the best and the poorest responders using the same
baseline criteria to see whether the factors associated
with poor response deviated from those found in the

Table 7 Comparison of first-year growth for patients with IGHD who had all the characteristics of the best responders
with those predicted to be poor responders
Variable

Predicted best first-year
HV SDS criterion n = 28

Predicted poor first-year
HV SDS criterion n = 29

< −3

> −2.5

Baseline BMI SDS

> −0.5

< −1

Pre-treatment HV (cm/yr)

< 3.5

>4

Baseline height SDS

Baseline height SDS minus mid-parental target height SDS

>3

<2

Maximum stimulated GH (ng/mL)

≤4

≥7

Female (n)/male (n)

5/23

7/22

Mean (SD)

Mean (SD)

Baseline age (yr)

6.5 (1.8)

6.8 (2.0)

Baseline height SDS

−4.1 (0.7)

−1.9 (0.3)

Baseline BMI SDS

0.5 (0.8)

−1.5 (0.5)

Pre-treatment HV (cm/yr)

1.9 (1.0)

6.2 (1.9)

Baseline height SDS minus mid-parental target height SDS

4.2 (0.7)

1.4 (0.5)

Maximum stimulated GH (ng/mL)

1.9 (1.0)

8.6 (0.8)

First-year HV (cm/yr)

13.1 (2.7)

9.1 (2.3)

First-year Bakker HV SDS

1.21 (1.3)

−0.51 (0.9)

Second-year HV (cm/yr)

8.5 (2.0)

7.3 (1.4)

Second-year Bakker HV SDS

0.33 (1.3)

−0.37 (0.8)

BMI, body mass index; HV, height velocity; GH, growth hormone; SDS, standard deviation score.
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average responders to the same degree but in the
opposite direction as the best responders. The fact that
there was a much greater separation between the best
and average responders compared with the average and
poor responders suggests that the best responders
make up a more distinct subset of patients than do the
poor responders. Poor response to GH may stem from
factors we have not assessed, such as undefined genetic
differences in skeletal responsiveness and poor compliance
with treatment. While we do not have any data on compliance, such issues with GH treatment are not uncommon
[10,11]. Age and dose were eliminated as predictors of
response for both IGHD and ISS in our analysis because
they were similar between the comparison groups. Of the
pre-Rx variables that differed between the patients, we
found that the best responders in both the IGHD and
ISS groups had lower pre-Rx HVs and higher BMI,
with differences seen only during the first year of therapy; second-year responsiveness to GH was not related
to pre-Rx HV. Lower peak stimulated GH and taller
parents predicted second-year responsiveness in the
patients with IGHD; there were no strong predictors of
second-year responsiveness in the ISS group.
For comparison, in an analysis of 169 Swedish prepubertal children with a mean age of 8.3 years and a wide range
of stimulated GH levels, all treated with 0.1 U/kg/day,
Kristrom et al. reported that the maximum GH after
arginine-insulin, age at start of treatment, mid-parental
height SDS, pre-Rx height SDS and HV, and the difference between pre-Rx height SDS and mid-parental
height SDS (diff SDS) all showed significant correlations
(r = 0.22 to 0.43) with the increase in height SDS over 2
years of therapy [1]. By stepwise linear regression, diff
SDS and log GHmax were the strongest predictors. Using
the KIGS database for patients with only IGHD, Geffner
and Dunger [12] reported that degree of GH deficiency,
age, height – mid-parental height SDS, and weight SDS
(which correlated strongly with height SDS) were, in
that order, the variables most predictive of HV during
the first year of therapy. For children with ISS, Ranke
et al. [13] reported that by multivariate linear regression,
the four variables associated with first-year response to
GH were age, GH dose, height – mid-parental height
SDS, and weight SDS. In both examples, if you eliminate
age and dose, the degree of GH deficiency remains the
most consistent variable.
For IGHD, it is clear that the best response in the first
and second years was seen in the patients with the
greatest difference between starting height and the target
height. More recently, Lee et al., using the ANSWER
study database involving 698 children with IGHD, found
that the change in HV at 4 months, baseline age, baseline height SDS, and baseline BMI SDS were, in that
order, the best predictors of the increase in height SDS
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at 1 and 2 years after starting GH; they did not report
predictors of response for their smaller group of 123
children with ISS [3]. We found more predictors of
excellent response to GH therapy in the IGHD group
than in the ISS group, and several of these predictors
for IGHD but not for ISS had significant effects into
the second year.
One unique aspect of this study was our ability to see
how the classification of IGHD and ISS responses to
rhGH, which were found during the first year of therapy,
changed when these groups were followed into the
second year. One might have predicted that the best and
poorest responders during the first year would largely
remain in the same categories during the second year,
but this was not the case. While a large proportion
(42%) of patients with IGHD who were best responders
in the first year remained in this group during the second
year, and relatively few (4%) became poor responders, a
greater proportion (58%) of the IGHD first-year poor
responders became average responders during the second
year, with only 37% remaining poor responders during
the second year. In the ISS group, the comparable
second-year numbers were 53% moving from poor to
average responders and 36% remaining poor responders. A
potential weakness of the analysis is that our results may
have been biased by the possibility that some children who
responded poorly during year 1 may have been taken off
treatment by either the physician or by the family; they
would not show up in our analysis because we only
looked at patients completing 2 years of therapy. Our
drop out analysis confirms that bias since those who
did drop out tended to have a somewhat poorer height
velocity, albeit only about 5% on average less than
those who remained in the study for 2 years. Nevertheless,
most of those who grew poorly in the first year but who
continued treatment grew satisfactorily or well during the
second year.
There are important implications of these findings.
First, as suggested above, poor responders may be more
similar to average responders than to best responders.
Second, as Tanner et al. demonstrated some 46 years
ago [14], in general, the correlation of height gain in
prepubertal children from year to year is only about 0.3
and this may underlie growth responsiveness to hormonal treatment as well. Compliance may also be a factor
as could changes in the psychosocial environment [15].
Thus, these findings suggest that a suboptimal first-year
growth response does not always predict a continued
poor response in the second year. The treating physician
may consider continuing therapy into the second year,
with appropriate attention to factors such as compliance
and psychosocial factors, and the knowledge that there
may be episodic changes in HV that are inherent to the
growth process and not obscured by GH treatment.
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Conclusion
In an analysis based on comparing patients with IGHD
of the same age and rhGH dose, the characteristics
contributing to the best first- and second-year responses
were those that describe the patients with classical
IGHD: lower pre-Rx HV, lower baseline height SDS,
higher BMI SDS, taller parents, and lower maximum stimulated GH. For patients with ISS, few characteristics stood
out. During the first year, lower pre-Rx HV and higher
BMI SDS predicted better growth. Year 1 HV SDS, greater
baseline height SDS and lower stimulated GH predicted
second-year HV SDS. For nearly all criteria examined, the
difference between the best and average responders was
much greater than the difference between average and
poor responders, suggesting that factors we were not
able to assess (e.g. inherent biologic and genetic variation
in growth, compliance, and social factors) may contribute
more to their suboptimal response to therapy. For
both IGHD and ISS, HV SDS in the first year was
not a strong predictor of HV SDS in the second year,
indicating that the use of the first-year HV alone to
make a decision regarding GH continuation is not
supported by these data.
Additional file
Additional file 1: Height velocity in short children during second
and third year of growth hormone treatment.
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